Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver

被引:43
作者
Honma, W
Shimada, M
Sasano, H
Ozawa, S
Miyata, M
Nagata, K
Ikeda, T
Yamazoe, Y
机构
[1] Tohoku Univ, Div Drug Metab & Mol Toxicol, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan
[2] Tohoku Univ, Sch Med, Dept Anat Pathol, Sendai, Miyagi 980, Japan
[3] Natl Inst Hlth Sci, Div Pharmacol, Tokyo 158, Japan
[4] Sankyo Co Ltd, Pharmacokinet Drug Delivery Res Labs, Tokyo 140, Japan
关键词
D O I
10.1124/dmd.30.8.944
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Since sulfation is the main metabolic pathway of troglitazone, accounting for about 70% of the metabolites detected in human plasma, we have aimed to identify human cytosolic sulfotransferases catalyzing the sulfation of troglitazone and to examine a possible role of the sulfation in the cytotoxicity observed in cell lines of human origin (HepG2 and Hep3B). Experiments using the recombinant sulfotransferases and human liver cytosols indicated that phenol sulfotransferase (ST1A3) and estrogen sulfotransferase (ST1E4) were the sulfotransferases most active toward troglitazone. Immunoblot analyses indicated that hepatic content of ST1A3 is about 13 times higher than that of ST1E4, suggesting that ST1A3 is mainly responsible for the sulfation of troglitazone in the liver. Lactate dehydrogenase (LDH) leakage was elicited by troglitazone in a concentration-dependent manner in the hepatoma cells. The troglitazone metabolites (the sulfate, glucuronide, and quinone forms) caused negligible LDH leakage. These findings suggest that accumulation of unmetabolized troglitazone causes the cytotoxicity in the hepatoma cells and may be responsible for toxicity in human liver.
引用
收藏
页码:944 / 949
页数:6
相关论文
共 36 条
  • [21] Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study
    Loi, CM
    Randinitis, EJ
    Vassos, AB
    Kazierad, DJ
    Koup, JR
    Sedman, AJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (12) : 1114 - 1120
  • [22] Pharmacogenetics of sulfotransferase
    Nagata, K
    Yamazoe, Y
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2000, 40 : 159 - 176
  • [23] Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines
    Ozawa, S
    Tang, YM
    Yamazoe, Y
    Kato, R
    Lang, NP
    Kadlubar, FF
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 1998, 109 (1-3) : 237 - 248
  • [24] Sulfating-activity and stability of cDNA-expressed allozymes of human phenol sulfotransferase, ST1A3*1 (213Arg) and ST1A3*2 (213His), both of which exist in Japanese as well as Caucasians
    Ozawa, S
    Shimizu, M
    Katoh, T
    Miyajima, A
    Ohno, Y
    Matsumoto, Y
    Fukuoka, M
    Tang, YM
    Lang, NP
    Kadlubar, FF
    [J]. JOURNAL OF BIOCHEMISTRY, 1999, 126 (02) : 271 - 277
  • [25] Covalent binding of xenobiotics to specific proteins in the liver
    Pumford, NR
    Halmes, NC
    Hinson, JA
    [J]. DRUG METABOLISM REVIEWS, 1997, 29 (1-2) : 39 - 57
  • [26] Phenol sulfotransferase pharmacogenetics in humans: Association of common SULT1A1 alleles with TS PST phenotype
    Raftogianis, RB
    Wood, TC
    Otterness, DM
    VanLoon, JA
    Weinshilboum, RM
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 239 (01) : 298 - 304
  • [27] SHIBATA H, 1993, J CLIN THER MED, V9, P1503
  • [28] Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells
    Takahashi, N
    Okumura, T
    Motomura, L
    Fujimoto, Y
    Kawabata, I
    Kohgo, Y
    [J]. FEBS LETTERS, 1999, 455 (1-2): : 135 - 139
  • [29] Toxic effect of troglitazone on cultured rat hepatocytes
    Toyoda, Y
    Tsuchida, A
    Iwami, E
    Miwa, I
    [J]. LIFE SCIENCES, 2001, 68 (16) : 1867 - 1876
  • [30] Hepatic dysfunction associated with troglitazone
    Watkins, PB
    Whitcomb, RW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) : 916 - 917